13th Euro Abstracts A449 despite adequate treatment. About 30% of patients do not achieve remission after 4 different antidepressant treatment trials (Rush et. Al., 2006). a few studies have examined the economic burden of TRD, but none have investigated the cost associated with more chronic and extensive forms of TRD characterized by non-response to four or more treatment trials. The objective of this study is to compare the direct medical expenditures of TRD patients to chronic MDD patients. METHODS: Patients with chronic MDD (defi ned as 2 or more years of continuous treatment) and patients with very severe TRD (defi ned as switching, augmentation, or addition of at least four qualifying therapies) were identifi ed in the PharMetrics Patient-Centric Database. Medical resource utilization (MRU) and payer costs per patient per year enrolled in the plan were compared. Patients were matched on duration of enrollment, length of depression, medications taken, and age. Statistical signifi cance was assessed using Student's t-tests. RESULTS: The average medical expenditures per TRD (n = 31,803) patient per year enrolled was $12,260 compared to $7,619 for non-TRD chronic MDD patients (n = 50,092) (p < 0.001), representing 60.9% higher costs per year. The differences in annual medical expenditures per TRD patient were primarily driven by higher medical and pharmacy MRU (number of services per patient) relative to the chronic MDD group (70.3 vs. 107.6, p < 0.001). CONCLUSIONS: Our results demonstrate that TRD patients accrued signifi cantly higher per patient medical costs than MDD patients due to higher medical resource use. These fi ndings suggest that more effective non-pharmacological alternative interventions are needed.
c9366 incurred during the index hospitalization. In the 3 months before the index hospitalization, average costs of c297 and in the 3 months after the index hospitalization costs of c2322 incurred for outpatient care, inpatient care, medications, rehabilitation, occupational therapy, and sick leave payments. 42.5% of the patients had at least one rehospitalization after the index hospitalization and mean costs of c8710 incurred during the fi rst rehospitalization. In the 4 weeks before the fi rst rehospitalization average costs of c1310 and in the 3 months after the rehospitalization costs of c2834 incurred. With any further rehospitalization costs for the inpatient care itself are decreasing slightly but overall costs for schizophrenia related medical care before and after the event are increasing. CONCLUSIONS: Impact and costs of hospitalization in schizophrenia are signifi cant, especially if the costs before and after hospitalization were taken into account. Rehospitalizations are a frequent event in schizophrenia care with high impact on costs. Further studies including the predictors of hospitalization are needed.
PMH21 SOCIETAL COSTS OF BIPOLAR DISORDER-THE CASE OF SWEDEN
Ekman M 1 , Granström O 2 , Omerov S 3 , Jacob J 2 , Landén M 4 1 i3 Innovus, Stockholm, Sweden; 2 AstraZeneca Nordic MC, Södertälje, Sweden; 3 Northern Stockholm Psychiatry, Stockholm, Sweden, 4 Gothenburg University, Göteborg, Sweden OBJECTIVES: To investigate the health care resource utilization and costs for Swedish bipolar disorder patients. METHODS: Registry data on socio-demographics and disease-related resource use during 2006-2008 was collected for 1846 patients with bipolar disorder. Health care visits and hospitalizations were obtained from the Northern Stockholm psychiatric clinic, while data on pharmaceuticals and sick leave were obtained from the national pharmaceutical registry and the Swedish social insurance agency, respectively. Community care data was obtained from the Swedish quality registry for bipolar disorder (BipoläR). Indirect costs were valued according to the human capital method. Costs across mood episodes (manic, depressive, and unspecifi ed) as well as remission were calculated. a patient for which >70 days had passed since the last new episode or inpatient visit, was defi ned as being in remission. RESULTS: The mean annual cost per patient with bipolar disorder was estimated at c24,300 (SEK 242,810) in 2009 prices, of which 23% represented direct treatment costs. The costs per month for active bipolar disorder were c6800 during depression, c6300 during mania, EUR 6,100 during unspecifi ed episodes, and c1500 for patients in remission. a patient who was not hospitalized during 2006-2008 generated a mean annual cost of c18,900, whereas a patient who was hospitalized at least once every year 2006-2008 generated mean annual costs of c67,600. CONCLUSIONS: Societal costs for bipolar disorder were more than 3.5 times higher for patients who were admitted at least once per year in 2006-2008 compared to those who were not hospitalized. Monthly costs during a depressive or manic episode were more than 4 times higher than during remission. Attempts to prevent mood episodes by means of effective treatment may not only decrease patient suffering, but also have the potential to dramatically reduce the societal cost of illness. Helmholtz Zentrum München-German Research Center for Environmental Health (GmbH), Neuherberg, Germany; 2 AOK-Bayern /die Gesundheitskasse, Nürnberg, Germany; 3 Pfi zer Deutschland GmbH, Berlin, Germany; 4 Federal Association of the AOK, Berlin, Germany; 5 University Hospital Erlangen, Erlangen, Germany OBJECTIVES: Rising life expectancy is associated with increasing prevalence of dementia in European countries. With progressing disease severity patients' call on health care services and social support grows. Several studies stress the burden imposed on family members caring for dementia-patients. However, empirical data assessing the economic value of informal care compared to health insurance expenditures is scarce. Within the cluster-randomized IDA study health care service utilization and informal caregiving time were assessed for 383 community living individuals suffering from mild to moderate dementia. METHODS: To examine costs from a health insurance perspective administrative data on all types of services provided were collected and valued with corresponding administrative prices over a three-year period. Patients' caregivers reported in yearly interviews the hours daily dedicated to the patient in care and supervision. The time provided for informal caregiving was valued by applying hourly wages of a nursing service and a domestic help respectively. Total costs and cost components were calculated from societal perspective and payers' point of view and analyzed by relevant subgroups. RESULTS: Caring for a homedwelling dementia-patient amounts annually to around c47.000 from societal perspective with informal care covering nearly 80% of this sum. For a patient with moderate dementia values assigned to informal care are approximately 70% higher than for a person with mild dementia. Health insurance has to spend c10,000 for an average dementia-patient per year, with services for long-term care representing the most costly part. CONCLUSIONS: Informal care is the major cost component in care for dementia, and it is strongly rising with disease progression. Changes in family structures and traditional living arrangements thus pose an enormous challenge regarding the future organization of dementia care. To maintain today's care-setting, concepts fostering community-based dementia care and support to family caregivers need to be further developed.
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PMH23 COSTS OF A COMMUNITY SUPPORT PROGRAM FOR DEPRESSION: RESULTS FROM THE BEAT THE BLUES (BTB) TRIAL
Thomas Jefferson University, Philadelphia, PA, USA; 2 Thomas Jefferson University, Newtown, PA, USA; 3 Center in the Park, Philadelphia, PA, USA OBJECTIVES: Literature on the costs of community support programs is scant. Beat the Blues (BTB) is a home support program for depression which involves trained social workers who meet with participants to identify care management concerns, make referrals and linkages, provide depression education, develop tailored action plans to accomplish identifi ed behavioral goals and enhance engagement in pleasurable activities, and teach stress reduction techniques for managing daily stressors (e.g., deep breathing). The primary objective of this study is to assess the cost of implementing BTB in African American elders with depressive symptoms. METHODS: The cost analysis is piggybacked onto the parent BTB trial, which employs randomized twogroup experimental design (treatment vs. control). Candidates are screened twice for depressive symptoms (PHQ-9 score > 5) to determine eligibility. Participants are randomly assigned to intervention or waitlist control. BTB is administered over 4 months with assessments in both groups at baseline and 4-months. Cost components comprise 4 main categories (Screening, Intervention Delivery, Supervision, and Other). Senior center management and social workers (interventionists) kept detailed logs of time spent conducting each component. The cost of conducting the intervention was calculated as the time spent performing each task multiplied by wage rate of the individual who performed the task. Non-time related cost (material and mileage) was also calculated. RESULTS: A total of 166 participants received the intervention. Average cost of BTB was $342 per person. The most costly aspect of BTB per person was cost of program delivery ($275), followed by materials ($48).The least costly aspect of the intervention was time spent supervising interventionists ($9). CONCLU-SIONS: This study informs decision makers about the resources required for depression community support interventions, which are not typically reimbursable through private or public health care programs. Results can also inform decision making regarding the costs of such interventions in relation to pharmacological treatments.
PMH24 HEALTH CARE UTILIZATION OF MAJOR DEPRESSIVE DISORDER PATIENTS
Myrén KJ, Löfroth E, Dahlberg E IMS Health, Stockholm, Sweden OBJECTIVES: To analyze the health care utilization by patients diagnosed with major depressive disorder (MDD). METHODS: This was a retrospective longitudinal descriptive database study of the utilization of health care by patients with MDD from the South-West region of Sweden (1.5 million inhabitants). All patients who were diagnosed with MDD (ICD-10 F32 or F33) during 2007 were included in the study. All costs from health care visits when an MDD was the primary diagnose were included as well as all cost from all dispensed antidepressant (ATC N06A) drugs. RESULTS: A total of 37,445 patients had at least one health care visit with an MDD diagnoses during 2007 in the South-West region of Sweden. Sixty-two percent of the patients had at least one visit to the primary care, 35% had been treated as out-patient, 9% had been treated by private physician, and 7% had been treated by in-patient care; 73% had at least one dispensed drug. The total health care cost, including drug cost, was 683 million SEK. 35% were from drugs and 23%, 26%, 14%, and 1% were from in-patient, out-patient, primary, and private care. During 2007 the average drug cost per patient, who utilize the current treatment, was 8847 SEK for drugs. The average cost for in-patient care was 64,576 SEK and 13,859 SEK for out-patient care. For primary and private care the average cost was 4268 SEK and 1342 SEK. CON-CLUSIONS: The cost for antidepressant drugs was the largest part of the total health care cost for MDD, 35%. The in-patient care was the greatest cost per patient. The relevant question is what mix of drugs should be prescribed in order to minimize the total health care cost. Further research needs to be preformed.
PMH25 COMPARISON OF ESCITALOPRAM VS. CITALOPRAM AND VENLAFAXINE IN THE TREATMENT OF MAJOR DEPRESSION IN SPAIN: CLINICAL AND ECONOMIC CONSEQUENCES
Sicras-Mainar A 1 , Blanca-Tamayo M 2 , Gimeno-de la Fuente V 3 , Salvatella-Pasant J 3 , Navarro-Artieda R 4 1 Directorate of Planning, Badalona Serveis Assistencials, Badalona, Barcelona, Spain; 2 Badalona Serveis Assistencials SA, Barcelona, Spain; 3 Lundbeck España SA, Barcelona, Spain; 4 Hospital Germans Trias i Pujol, CIBEREHD, Barrcelona, Spain OBJECTIVES: Population based study to determine clinical consequences and economic impact of using escitalopram (ESC) vs. citalopram (CIT) and venlafaxine (VEN) in patients initiating treatment for a new episode of major depression (MD), in real-life conditions of outpatient practice. METHODS: Observational, multicenter, retrospective study conducted using computerized medical records (administrative databases) of patients treated in six primary care centers and two hospitals between January 2003 and March 2007. Study population: patients >20 years of age diagnosed with a new episode of MD who initiate treatment with ESC, CIT or VEN, and whithout any antidepressant treatment within the previous 6 months, who were followed for 18 months or more. Main variables: socio-demographic variables, remission, comorbidity, annual health care costs (medical visits, diagnostic and therapeutic tests, hospitalizations, emergency room and psychoactive drugs prescribed) and non-health care costs (productivity loss at work). Statistical analyses: logistic regression and ANCOVA models. RESULTS: A total of 965 patients (ESC = 131; CIT = 491; VEN = 343) were included. ESC-treated patients were younger, with a higher proportion of males, and a lower specifi c comorbidity (P < 0.01). ESC-treated patients achieved higher remission rates (58.0%) compared to CIT (38.3%) or VEN (32.4%) patients (P < 0.001) and had lower productivity work ESC (37.9 days) vs.CIT (32.7 days) or vs. VEN (43.8 days), p = 0.042. No differences in average/unit costs of psychoactive drugs were observed between the ESC and CIT groups (c294.7 vs. c265.2), with higher costs seen in the VEN group (c643.0), p = 0.003. In the corrected model, total (health care and non-health care) costs were lower with ESC (c2276.2) vs. CIT (c3093.8), p = 0.047 and VEN (c3801.2), p = 0.045. CONCLUSIONS: ESC appears to be dominant in the treatment of new MD episodes when compared to CIT and VEN, resulting in higher remission rates and lower total costs. The study was done from the provider perspective using activity based costing that includes both capital and variable cost associated with MMT program. RESULTS: Most of the respondents were male (99%) with mean age of 38.5 years. Most (72.5%) of them were Malay and 50.5% working in semi or unskilled manual job with basic salary less than MYR1000 (US$312). Most (99.5%) were smoker with history of heroin addiction of more than 10 years. The median length of MMT treatment was 14 months. Fifty-seven percent of the patients were suffering from chronic disease. The capital cost for MMT program was US$8013.16 and the variable cost of providing a month of treatment per patient was US$50.43. Approximately 47.19% of this was for methadone and personnel cost accounted for 31.94%. The variable cost was statistically higher (P < 0.05) in patients present of chronic disease. CONCLUSIONS: This study estimated the variable cost of MMT treatment per patient in Malaysia (US$50.43/month) is less expensive compare USA (US$220/month, Jones et al., 2009 ). These cost data may be useful to policymakers and researchers for further developing the program.
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